Further launches will observe during the year in European countries and across the world.

Hans-Joachim Lohrisch, President and CEO of Altana Pharma. In addition to the recently launched inhaler Alvesco, for which cooperation partner sanofi-aventis has filed an application in the U already.S. And cooperation partner Teijin in Japan, the family also includes Ciclesonide nasal spray , Ciclesonide as a fixed combination item with formoterol and Ciclesonide as a dry powder inhaler . Related StoriesNew therapy attacks the source of asthma, treats the condition at cellular levelSecondhand smoke exposure doubles risk of hospitalization for children with asthmaResearchers find protein that plays crucial role in development of allergic airway inflammationUK offered as the Reference Member State for the Mutual Recognition Treatment of Alvesco in various other European countries.Related StoriesMD Anderson study reveals why chemotherapy medications not effective for many pancreatic cancer patientsMeat-rich diet plan may increase kidney cancers riskOvarian cancer patients with a history of oral contraceptive use have better outcomes THE INITIAL system, with its capacity for fast RapidArc treatments, markedly enhances our treatment capability, stated Dr. Brian Yu, Head of Radiation Oncology, Prince of Wales Medical center. It was developed to provide advanced cancer tumor care to more individuals around the world. It incorporates Varian’s verified systems for reliable and constant dose control, delivery, and beam shaping. Using its speed and picture guidance features, UNIQUE enables cancer treatment centers to provide quality care to more patients better value per treatment, said Tom Duffy, Varian’s vice president of product sales and advertising for the Asia Pacific region.